Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Drug-eluting stents offer downstream savings

    • 12 Accesses

    This is a preview of subscription content, log in to check access.

    REFERENCE

    1. 1.

      Bakhai A, Stone GW, Mahoney E, Lavelle TA, Shi C, Berezin RH, Lahue BJ, Clark MA, Lacey MJ, Russell ME, Ellis SG, Hermiller JB, Cox DA, Cohen DJ, TAXUS-IV Investigators.Cost effectiveness of paclitaxel-eluting stents for patients undergoing percutaneous coronary revascularization: results from the TAXUS-IV Trial. Journal of the American College of Cardiology 48: 253-261, No. 2, 18 Jul 2006

    2. 2.

      Elezi S, Dibra A, Folkerts U, Mehilli J, Heigl S, Schömig A, Kastrati A.Cost analysis from two randomized trials of sirolimus-eluting stents versus paclitaxel-eluting stents in high-risk patients with coronary artery disease. Journal of the American College of Cardiology 48: 262-267, No. 2, 18 Jul 2006

    3. 3.

      Vaitkus PT.Common sense, dollars and cents, and drug-eluting stents. Journal of the American College of Cardiology 48: 268-269, No. 2, 18 Jul 2006

    Download references

    Rights and permissions

    Reprints and Permissions

    About this article

    Cite this article

    Drug-eluting stents offer downstream savings. Pharmacoecon. Outcomes News 510, 7 (2006). https://doi.org/10.2165/00151234-200605100-00017

    Download citation

    Keywords

    • Sirolimus
    • Bare Metal Stents
    • Target Vessel Revascularisation
    • Angiographic Result
    • Repeat Revascularisation